"French techbio company Cure51 has partnered with NVIDIA to accelerate its research into a rare phenomenon: cancer patients who survive against the odds. These outliers, as Cure51 calls them, are the focus of an effort to build a large-scale multi-omics database that could reveal new therapeutic targets. The company is using artificial intelligence (AI)-accelerated tools to support its work, as it scales up sample analysis across a global network of cancer centers. On NVIDIA’s side, it’s not its first move in biotech, far from it."
Read more
